EGFR and neoplasm: The combination of EGFR inhibitors gefitinib and lenvatinib shows effective anti-proliferation effects in EGFR-expressing liver cancer cell lines, mouse liver cancer xenograft tumor models, genetically engineered mouse orthotopic liver cancer models, and PDX liver cancer models.